Pepgen

PepGen develops an oligonucleotide platform for neuromuscular and cardiac diseases, using peptides to deliver therapies to targeted tissues like the heart.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2022
Stage of Initial Investment
Series A
Initial Investment Year
2020